During the past decade, Hospital Regional Universitario de Malaga conducted 304 clinical trials. In the 10-year time frame, 304 clinical trials started and 92 clinical trials were completed, i.e. on average, 30.3% percent of trials that started reached the finish line to date. In the past 5 years, 176 clinical trials started and 62 clinical trials were completed. i.e. 35.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital Regional Universitario de Malaga" #1 sponsor was "Janssen Research & Development, LLC" with 18 trials, followed by "PETHEMA Foundation" with 17 trials sponsored, "Pfizer" with 17 trials sponsored, "Hoffmann-La Roche" with 13 trials sponsored and "Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud" with 13 trials sponsored. Other sponsors include 346 different institutions and companies that sponsored additional 191 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Regional Universitario de Malaga" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 8 trials as a collaborator, "Pfizer" with 8 trials as a collaborator, "Eli Lilly and Company" with 7 trials as a collaborator, "Hoffmann-La Roche" with 7 trials as a collaborator and "Merck Sharp & Dohme LLC" with 6 trials as a collaborator. Other collaborators include 227 different institutions and companies that were collaborators in the rest 168 trials.

According to Clinical.Site data, the most researched conditions in "Hospital Regional Universitario de Malaga" are "Carcinoma, Non-Small-Cell Lung" (13 trials), "Hemophilia A" (11 trials), "Non-small Cell Lung Cancer" (11 trials), "Non Small Cell Lung Cancer" (9 trials) and "Acute Lymphoblastic Leukemia" (8 trials). Many other conditions were trialed in "Hospital Regional Universitario de Malaga" in a lesser frequency.

Most popular intervention types in "Hospital Regional Universitario de Malaga" are "Drug" (310 trials), "Other" (41 trials), "Biological" (35 trials), "Device" (17 trials) and "Procedure" (15 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (73 trials), "Carboplatin" (17 trials), "Cisplatin" (16 trials), "Docetaxel" (13 trials) and "Pembrolizumab" (13 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Regional Universitario de Malaga" are 391 trials for "All" genders, 21 trials for "Female" genders and 16 trials for "Male" genders.

Currently, there are NaN active trials in "Hospital Regional Universitario de Malaga". 5 are not yet recruiting, 110 are recruiting, 59 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 186 completed trials in Hospital Regional Universitario de Malaga, 1 suspended trials, and 41 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Regional Universitario de Malaga, 27 "Phase 1" clinical trials were conducted, 121 "Phase 2" clinical trials and 158 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 40 trials, and there were also 23 trials that are defined as “Not Applicable".

Hospital Regional Universitario de Malaga has several departments that took part in Clinical trials: "Hospital Regional Universitario Carlos Haya; Servicio de Oncologia" - 19 trials, "Hospital Regional Universitario de Malaga - Hospital General; Servicio de Neurologia" - 11 trials, "Hospital Regional Universitario Carlos Haya; Servicio de Hematologia" - 2 trials, "Hospital Regional Universitario de Malaga; Servicio de Reumatologia" - 2 trials